AI-Designed Drug Rentosertib Reverses Biological Age by 3-4 Years in Clinical Trial
Insilico Medicine's rentosertib, an AI-generated drug for lung disease, reduced biological age markers by 3-4 years across six proteomic aging clocks in a 42-patient Phase IIa trial. Published in Nature Biotechnology, the study marks the first clinical evaluation of a drug featuring both an AI-discovered target and AI-designed molecule for aging and disease biology.